Drugs / VLP Peanut
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05476497 | Oct 2022 → Nov 2026 expected | food allergy | Allergy Therapeutics | Active not recruiting | Met primary |
News releases announcing trial results or a regulatory action · 16
| Date | Issuer | Release |
|---|---|---|
| 2026-06-12 | Allergy Therapeutics | Results Allergy Therapeutics to present at EAACI 2026 allergytherapeutics.com ↗
The PROTECT trial met the primary endpoint, demonstrating a benign safety profile of VLP Peanut, with a strong dose-response in immunomodulating tolerogenic immune responses induced confirming clinical proof of concept. |
| 2026-03-04 | Allergy Therapeutics | Results Positive Biomarker Results from PROTECT Trial allergytherapeutics.com ↗
Allergy Therapeutics (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy immunotherapies, today announces consistent biomarker results from its Phase I/IIa PROTECT trial, supporting the strong immunomodulating potential of the product. |
| 2026-02-26 | Allergy Therapeutics | Results Allergy Therapeutics presents progress at AAAAI allergytherapeutics.com ↗
Positive safety, tolerability and interim biomarker data from the Phase I/IIa PROTECT clinical trial of VLP Peanut, the Group's innovative, short-course peanut allergy immunotherapy candidate, in healthy and peanut-allergic adults, confirming its potential as a promising therapeutic candidate for peanut allergy treatment |
| 2025-12-09 | Allergy Therapeutics | Results Primary Safety Endpoint Met in PROTECT trial allergytherapeutics.com ↗
Preliminary safety data from 48 participants demonstrate that a 2000-fold increase in dose from the starting dose has been safe and well tolerated, including in both peanut -allergic patients and healthy participants . |
| 2025-10-16 | Allergy Therapeutics | Results Further progress in Phase I/IIa PROTECT trial allergytherapeutics.com ↗
No relevant safety signals were identified across each of the trial's cohorts, which supports the safety profile of VLP Peanut. |
| 2025-02-27 | Allergy Therapeutics | Results Presentations at 2025 AAAAI / WAO Joint Congress allergytherapeutics.com ↗
Supporting safety and tolerability data from the ongoing Phase I/IIa PROTECT clinical trial of the Group's novel virus-like-particle (VLP)-based peanut allergy vaccine candidate ("VLP Peanut") in peanut allergic patients, which reported positive interim biomarker efficacy data in December 2024 |
| 2024-12-04 | Allergy Therapeutics | Results Positive Interim Data from PROTECT Trial allergytherapeutics.com ↗
Allergy Therapeutics announces positive interim analysis data from the Phase I/IIa VLP Peanut PROTECT Trial |
| 2024-09-17 | Allergy Therapeutics | Results Progression of patient cohorts in PROTECT Trial allergytherapeutics.com ↗
No relevant safety or tolerability issues were observed at these higher doses. |
| 2024-06-10 | Allergy Therapeutics | Results Progression of patient cohorts in PROTECT Trial allergytherapeutics.com ↗ |
| 2024-05-31 | Allergy Therapeutics | Results Allergy Therapeutics presents findings at EAACI allergytherapeutics.com ↗
The beneficial safety and tolerability results from the healthy subject subcutaneous dosing cohorts of the Phase I/IIa PROTECT trial of the Group's novel virus-like-particle (VLP)-based peanut allergy vaccine candidate ("VLP Peanut"), without any major safety or tolerability findings. |
| 2023-04-19 | Allergy Therapeutics | Results Skin-prick testing completes in PROTECT Trial allergytherapeutics.com ↗ |
| 2022-04-25 | Allergy Therapeutics | Results Allergy Therapeutics shares data at WAO-BSACI allergytherapeutics.com ↗
The mouse anaphylaxis model of peanut allergy demonstrated that the vaccine candidate exhibited a non-reactogenic profile after intravenous challenge with whole peanut extract. |
| 2022-03-01 | Allergy Therapeutics | Results Allergy Therapeutics shares positive new data allergytherapeutics.com ↗
Convincing data presented from VLP001 ex-vivo biomarker study show VLP Peanut has potential to modulate T cell, B cell and dendritic cell responses, promoting the protective tolerogenic pathway and highlighting the potential as an effective treatment for peanut allergy |
| 2022-01-26 | Allergy Therapeutics | Regulatory FDA clearance of IND application for VLP Peanut allergytherapeutics.com ↗
Allergy Therapeutics (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces that the United States Food & Drug Administration (FDA) has cleared the Group's Investigational New Drug application (IND) for its novel virus-like particle (VLP)-based peanut allergy vaccine candidate ("VLP Peanut"). |
| 2021-09-13 | Allergy Therapeutics | Results Secondary endpoints from VLP Peanut 001 allergytherapeutics.com ↗
The secondary endpoint results demonstrated a reduced IgE binding capacity to B cells of VLP Peanut suggesting a promising safety profile with reduced potency to induce allergic reactions. |
| 2021-08-03 | Allergy Therapeutics | Results Successful primary outcome of VLP Peanut 001 allergytherapeutics.com ↗
Allergy Therapeutics announces successful primary outcome of VLP Peanut 001 |
All press releases naming this drug 22 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VLP Peanut | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05476497 ↗ |
| Modality | Other / unclassified | “A cucumber mosaic virus-like particle expressing peanut allergen component Ara h 2 (VLP Peanut)” PMID 39756833 ↗ Jan 2025 |
| Route | Subcutaneous | “Each cohort will receive 6 ascending subcutaneous administrations of VLP Peanut.” NCT05476497 ↗ |